[Botulinum A in the treatment of equinus dynamic spasticity in children with cerebral palsy. Preliminary study]

M Mousny1, N Allington

  • 1Cliniques Universitaires St Luc, Bruxelles, Belgique.

Insights

Intramuscular botulinum-A toxin injections effectively treat spastic dynamic equinus deformities in children with cerebral palsy, improving gait and endurance. Further research with higher dosages is recommended to confirm these benefits.

Area of Science:

  • Neurology
  • Pediatrics
  • Orthopedics

Background:

  • Cerebral palsy (CP) often leads to spastic dynamic equinus deformities.
  • These deformities impact gait and mobility in affected children.
  • Botulinum-A toxin is a potential therapeutic agent for managing spasticity.

Purpose of the Study:

  • To evaluate the efficacy of intramuscular botulinum-A toxin injections for treating spastic dynamic equinus deformities in children with CP.
  • To assess improvements in gait, functional abilities, and endurance post-treatment.

Main Methods:

  • A prospective clinical study involving ten children (14 feet) with CP.
  • Treatment involved intramuscular injections of botulinum-A toxin (Botox) into specific leg muscles.
  • Clinical assessments and gait analysis were conducted before and at 1, 3, and 6 months post-injection.

Main Results:

  • All patients demonstrated clinical improvement.
  • Functional abilities and walking endurance increased in several children.
  • Improvements were observed in passive dorsiflexion, Physician Rating Scale scores, gait analysis, and reduced gastrocnemius spasticity.
  • Treatment effects lasted 3-6 months, with no reported side effects.

Conclusions:

  • Intramuscular botulinum-A toxin is a useful treatment for spastic dynamic equinus deformities in children with CP.
  • The study suggests a potential increase in patient walking endurance.
  • Further research with higher dosages is warranted to confirm efficacy and endurance benefits.
Abstract

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Alterations in Muscle Tone ll01:12

Alterations in Muscle Tone ll

Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...